NASALIGN
... The way to spray
The Problem

The global nasal drug delivery market is approximately $3 Billion annually

Using nasal sprays correctly is directly linked to efficacy, reduction of adverse events and patient satisfaction

There is no product on the market designed to accomplish this

The Problem
The Problem
The Problem
The Problem
The Problem
The Problem
The Problem
The Solution: Nasalign

Fits easily and comfortably inside the nose – different sizes available

Class I medical device

Used for Rx and OTC sprays

Guides spray to the proper target

Prevents over-insertion

Washable, re-usable, latex-free
Nasalign – Proof of Concept

- Initial prototype has been created and tested using various Rx and OTC spray devices
- No interference with spray plume
- Nozzle of typical nasal sprays fit easily into Nasalign
Next Steps

2012 – 2013
- Initial design and prototype creation ✓
- Filing of patent application ✓

2014-2015 ($250 K)
- Final designs and testing
- Patent prosecution
- Establishment registration
- Manufacturing and packaging
- Advertising and distribution

Global nasal drug delivery market - $3 Billion in 2012, CAGR 9%

$3 Billion → 5 Years → $4.5 Billion
Nasalign Intellectual Property Position

• Patent application sourced from Weill Cornell Medical College

• Pending claims in the patent encompass a spectrum of crucial embodiments including device design and utility

• Broad patent protection expected until at least 2033

• Nasalign IP portfolio will expand around design modifications and improvements, improved materials and modes of manufacturing as development progresses
Nasalign, LLC – Management Team

**Michael Nelson, JD,** is CEO and CFO of Nasalign and Boa-Bag and CFO of Allovate and Immunovent. Since graduating from Cornell University and receiving his law degree from New York University School of Law, he was CFO & general counsel of an early stage healthcare company, an analyst at Barclays Capital and ING, an investment banker at CIBC World Markets and practiced law at Willkie Farr & Gallagher and Dewey Ballantine. Mr. Nelson is currently the managing director and head of healthcare at Westwood Capital, LLC and president of Thea Capital Management, LLC, a healthcare advisory company.

**Erick Berglund, PhD,** is COO of Nasalign and CEO of Allovate and Immunovent. During his doctoral work at Boston University School of Medicine and at the Goethe University in Frankfurt, Germany, he gained concurrent industrial R&D experience as a scientist at Sanofi-Aventis. Afterwards, he developed intellectual property as a USPTO registered patent agent in Boston, serving early and established biopharmaceutical clients. Dr. Berglund then moved into business development and strategy capacities with both early-stage and globally established pharmaceutical firms, including Japanese companies while he lived in Tokyo.

**William Reisacher, MD,** is the inventor of Nasalign and Chief Scientific Advisor to Allovate and Immunovent. Dr. Reisacher graduated from Cornell University and received his medical degree from the Mount Sinai School of Medicine with Distinction in Research. He is an Associate Professor of Otolaryngology on the full-time faculty at Weill Cornell Medical College / NY-Presbyterian Hospital and the Director of Allergy. He is also on the Board of Directors of the American Academy of Otolaryngic Allergy (AAOA).
Take Home Points

• Nasalign is the first device of its kind to help make nasal spraying easy, safe and effective

• Efficacy + comfort – side effects = REFILLED PRESCRIPTIONS

• Nasalign – “The way to spray!”
Contact Information

Michael Nelson, JD
100 W 93rd St. #15F
646-494-8432
mnelson@westwoodcapital.com

Erick Berglund, PhD
Phone 646-895-0741
erick.berglund@gmail.com

William Reisacher, MD
646-962-2093
wir2011@med.cornell.edu